On-Q-lty (Waltham, MA) a development stage molecular diagnostics company incorporating microfluidics and biomarker panels to predict response to cancer therapy based on DNA repair pathways in tumors, closed a $5M Series A financing, bringing the total round to $26M. Participants include Atlas Venture, Mohr Davidow Ventures, Bessemer Venture Partners, Physic Ventures and Northgate Capital.
Note: [...]

ABT Molecular Imaging (Knoxville, TN) medical imaging company developing a production platform to generate unit doses of molecular imaging drugs for positron emission tomography (PET) scanning at the point of use, closed a $9M Series A financing. Participants include Intersouth Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Metabolon (Durham, NC) a metabolomics services and informatics company focused on detection of small molecule biomarkers, closed a $6M Series C financing, bringing the entire financing round to $12.3M. Participants include Syngenta Ventures, Fletcher Spaght Ventures, Sevin Rosen Funds, Aurora Funds, Harris and Harris Group, Fulcrum Financial Partners and Alexandria Equities.

GetWellNetwork (Bethesda, MD) a commercial stage telemedicine provider of interactive patient care solutions, closed a $10M Series C financing. Participants include Johnson & Johnson Development Corp., Valhalla Partners, Grosvenor Funds, Point Judith Capital and Village Ventures.

Singulex (Alameda, CA) commercial-stage developer of single molecule biomarker diagnostic assay systems, closed a $19M Series D financing. Participants include JAFCO Ventures, OrbiMed Advisors and Fisk Ventures.

BG Medicine (Waltham, MA) focused on the discovery, development and commercialization of molecular biomarkers and diagnostics, closed a $40M Series D financing. Participants include Legg Mason Capital Management, GE Asset Management, SmallCap World Fund, Flagship Ventures, Gilde Healthcare Partners, Humana, and Stelios Papadopoulos.

Astute Medical (San Diego, CA) developmental-stage company focused on the identification and validation of protein biomarkers, closed a $6.2M Series A financing. Participants include De Novo Ventures.

VisEn Medical (Woburn, MA) commercial-stage company focused on fluorescence in vivo imaging, closed a $5M Series B financing. Participants include Merck Capital Ventures and Flagship Ventures.

Caprotec Bioanalytics (Germany) maker of a mass-spec based compound capture platform for drug development and protein biomarker identification closed a $8.8M Series B financing. Participants include Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds and private investors.

Genizon Biosciences (Canada) is a therapeutic target and biomarker development stage company focused on Crohn’s disease, psoriasis, asthma and schizophrenia has closed a $31M Series D. Participants include BTF B.V.